Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd. (SHA:688076)
China · Delayed Price · Currency is CNY 33.78
-0.27 (-0.79%)
Feb 13, 2026, 3:00 PM CST
SHA:688076 Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Net Income | 498.69 | 404.39 | 162.94 | 129.11 | 115.39 | 123.44 |
Depreciation & Amortization | 209.29 | 209.29 | 135.55 | 99.96 | 84.77 | 70.71 |
Other Amortization | 7.73 | 7.73 | 4.61 | 4.72 | 4.25 | 6.41 |
Loss (Gain) From Sale of Assets | -0.5 | -0.5 | -0.18 | -18.89 | -0.06 | 3.82 |
Asset Writedown & Restructuring Costs | 9.7 | 9.7 | 15.3 | 0.45 | 2.31 | 0.3 |
Loss (Gain) From Sale of Investments | 1.72 | 1.72 | -3.16 | -19.98 | -3.22 | -6.43 |
Provision & Write-off of Bad Debts | 20.62 | 20.62 | 5.11 | 5.87 | 1.65 | 1.84 |
Other Operating Activities | 80.93 | 58.16 | 49 | 29.63 | 15.44 | 15.8 |
Change in Accounts Receivable | -348.97 | -348.97 | -126.49 | -145.04 | -45.88 | -42.32 |
Change in Inventory | -243.29 | -243.29 | -82.58 | -111.74 | -87.63 | -73.43 |
Change in Accounts Payable | 291.17 | 291.17 | 180.38 | 58.34 | 75.82 | 30.26 |
Change in Other Net Operating Assets | 32.63 | 32.63 | 23.3 | 1.71 | 8.77 | 7.02 |
Operating Cash Flow | 517.18 | 400.12 | 350.21 | 29.29 | 180.75 | 141.38 |
Operating Cash Flow Growth | 35.26% | 14.25% | 1095.59% | -83.79% | 27.84% | 206.44% |
Capital Expenditures | -1,464 | -1,090 | -660.64 | -438.36 | -233.36 | -111.28 |
Sale of Property, Plant & Equipment | 2.72 | 3.98 | 1.53 | 0.06 | 0.34 | 11.46 |
Divestitures | - | - | - | 13.12 | - | 17 |
Investment in Securities | -27.69 | -308 | -6 | -25.95 | -7 | -80.76 |
Other Investing Activities | 1.57 | 0.95 | 2.9 | 1.39 | 3.09 | 0.41 |
Investing Cash Flow | -1,487 | -1,393 | -662.21 | -449.74 | -236.93 | -163.18 |
Short-Term Debt Issued | - | - | - | - | 242.68 | - |
Long-Term Debt Issued | - | 1,698 | 1,146 | 388.99 | - | 291.38 |
Total Debt Issued | 2,772 | 1,698 | 1,146 | 388.99 | 242.68 | 291.38 |
Short-Term Debt Repaid | - | - | - | - | -422.79 | - |
Long-Term Debt Repaid | - | -901.76 | -454.73 | -129.65 | -4.11 | -242.83 |
Total Debt Repaid | -1,472 | -901.76 | -454.73 | -129.65 | -426.91 | -242.83 |
Net Debt Issued (Repaid) | 1,300 | 796.43 | 691.05 | 259.34 | -184.23 | 48.55 |
Issuance of Common Stock | 12.53 | 22.98 | - | - | 762.63 | - |
Common Dividends Paid | -212.04 | -118.75 | -57.61 | -40.57 | -6.04 | - |
Dividends Paid | -212.04 | -118.75 | -57.61 | -40.57 | -6.04 | - |
Other Financing Activities | 149.11 | 99.1 | -1.54 | 18.15 | -37.47 | -9.04 |
Financing Cash Flow | 1,250 | 799.75 | 631.9 | 236.91 | 534.89 | 39.5 |
Foreign Exchange Rate Adjustments | 6.72 | 8.34 | -3.21 | -0.82 | -1.58 | -7.73 |
Net Cash Flow | 286.31 | -184.98 | 316.69 | -184.35 | 477.13 | 9.98 |
Free Cash Flow | -946.61 | -690.01 | -310.43 | -409.07 | -52.61 | 30.1 |
Free Cash Flow Margin | -49.83% | -42.47% | -30.04% | -62.81% | -8.17% | 5.31% |
Free Cash Flow Per Share | -3.06 | -2.24 | -1.03 | -1.38 | -0.20 | 0.13 |
Cash Interest Paid | - | - | - | - | - | 11.63 |
Cash Income Tax Paid | 10.03 | 18.56 | 8.2 | -29.3 | -11.18 | -7.26 |
Levered Free Cash Flow | -1,031 | -856.88 | -374.23 | -441.9 | -133.86 | -70.96 |
Unlevered Free Cash Flow | -995.55 | -835.17 | -364.18 | -436.11 | -130.04 | -63.69 |
Change in Working Capital | -311 | -311 | -18.95 | -201.59 | -39.78 | -74.51 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.